Treatment of advanced basal cell carcinoma with sonidegib: Perspective from the 30-month update of the BOLT trial

Leon Chen; Alexander B. Aria; Sirunya Silapunt; Heng Huan Lee; Michael R. Migden

doi:10.2217/fon-2017-0457

Treatment of advanced basal cell carcinoma with sonidegib: Perspective from the 30-month update of the BOLT trial

Leon Chen, Alexander B. Aria, Sirunya Silapunt, Heng Huan Lee, Michael R. Migden

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

Sonidegib, a hedgehog pathway inhibitor, was approved by the US FDA for the treatment of locally advanced basal cell carcinoma which cannot be readily treated with surgery or radiotherapy. The pharmacology and pharmacokinetics of sonidegib will be discussed in this review. Additionally, an in-depth analysis of the BOLT trial and data from the 30-month update will be included. This will serve as an update to a previously published article which reported the 12-month update of the BOLT trial.

Original language	English (US)
Pages (from-to)	515-525
Number of pages	11
Journal	Future Oncology
Volume	14
Issue number	6
DOIs	https://doi.org/10.2217/fon-2017-0457
State	Published - Mar 2018

Keywords

BOLT
HPI
basal cell carcinoma
hedgehog pathway inhibitor
laBCC
locally advanced basal cell carcinoma
mBCC
metastatic basal cell carcinoma
sonidegib

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.2217/fon-2017-0457

Cite this

@article{f676e56d129e4780a7c3feaecf9b6b19,

title = "Treatment of advanced basal cell carcinoma with sonidegib: Perspective from the 30-month update of the BOLT trial",

abstract = "Sonidegib, a hedgehog pathway inhibitor, was approved by the US FDA for the treatment of locally advanced basal cell carcinoma which cannot be readily treated with surgery or radiotherapy. The pharmacology and pharmacokinetics of sonidegib will be discussed in this review. Additionally, an in-depth analysis of the BOLT trial and data from the 30-month update will be included. This will serve as an update to a previously published article which reported the 12-month update of the BOLT trial.",

keywords = "BOLT, HPI, basal cell carcinoma, hedgehog pathway inhibitor, laBCC, locally advanced basal cell carcinoma, mBCC, metastatic basal cell carcinoma, sonidegib",

author = "Leon Chen and Aria, {Alexander B.} and Sirunya Silapunt and Lee, {Heng Huan} and Migden, {Michael R.}",

note = "Publisher Copyright: {\textcopyright} 2018 Future Medicine Ltd.",

year = "2018",

month = mar,

doi = "10.2217/fon-2017-0457",

language = "English (US)",

volume = "14",

pages = "515--525",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "6",

}

TY - JOUR

T1 - Treatment of advanced basal cell carcinoma with sonidegib

T2 - Perspective from the 30-month update of the BOLT trial

AU - Chen, Leon

AU - Aria, Alexander B.

AU - Silapunt, Sirunya

AU - Lee, Heng Huan

AU - Migden, Michael R.

PY - 2018/3

Y1 - 2018/3

N2 - Sonidegib, a hedgehog pathway inhibitor, was approved by the US FDA for the treatment of locally advanced basal cell carcinoma which cannot be readily treated with surgery or radiotherapy. The pharmacology and pharmacokinetics of sonidegib will be discussed in this review. Additionally, an in-depth analysis of the BOLT trial and data from the 30-month update will be included. This will serve as an update to a previously published article which reported the 12-month update of the BOLT trial.

AB - Sonidegib, a hedgehog pathway inhibitor, was approved by the US FDA for the treatment of locally advanced basal cell carcinoma which cannot be readily treated with surgery or radiotherapy. The pharmacology and pharmacokinetics of sonidegib will be discussed in this review. Additionally, an in-depth analysis of the BOLT trial and data from the 30-month update will be included. This will serve as an update to a previously published article which reported the 12-month update of the BOLT trial.

KW - BOLT

KW - HPI

KW - basal cell carcinoma

KW - hedgehog pathway inhibitor

KW - laBCC

KW - locally advanced basal cell carcinoma

KW - mBCC

KW - metastatic basal cell carcinoma

KW - sonidegib

UR - http://www.scopus.com/inward/record.url?scp=85042873145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042873145&partnerID=8YFLogxK

U2 - 10.2217/fon-2017-0457

DO - 10.2217/fon-2017-0457

M3 - Article

C2 - 29119833

AN - SCOPUS:85042873145

SN - 1479-6694

VL - 14

SP - 515

EP - 525

JO - Future Oncology

JF - Future Oncology

IS - 6

ER -

Treatment of advanced basal cell carcinoma with sonidegib: Perspective from the 30-month update of the BOLT trial

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this